Related Experiment Video

Updated: Aug 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Being specific about race-specific medicine

Jonathan Kahn1, Pamela Sankar

  • 1Hamline University School of Law in St. Paul, Minnesota, USA.

Health Affairs (Project Hope)
|August 17, 2006
PubMed

Insights

This study clarifies that prescribing BiDil or its generics should not be based on race. The analysis indicates that race-blind prescribing ensures appropriate patient care without denying life-saving therapies.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Health Disparities

Background:

  • A previous analysis of BiDil prescribing practices was published.
  • Gary Puckrein's paper, "BiDil: From Another Vantage Point," critiqued this analysis.

Discussion:

  • Puckrein's paper misrepresents the original analysis.
  • The original analysis does not advocate for denying patients access to BiDil or its generics.
  • The evidence supports prescribing BiDil irrespective of patient race.

Key Insights:

  • The critique of the BiDil analysis by Puckrein is based on a misinterpretation.
  • The original analysis supports, rather than hinders, access to potentially life-saving therapies.
  • Prescribing decisions for BiDil should be race-neutral.

Outlook:

  • Further research into race-based medicine is warranted.
  • Clinical guidelines should emphasize evidence-based prescribing over racial categorizations.
  • Promoting equitable access to cardiovascular therapies is crucial.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...